Status:
COMPLETED
Acute Effects of E-Cigarette Aerosol Inhalation
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Endothelial Dysfunction
Biochemical Markers
Eligibility:
All Genders
18-35 years
Phase:
EARLY_PHASE1
Brief Summary
This study comprises a portion of a larger study designed to compare results of vascular function in non-smokers to vascular function in healthy smokers chronically exposed to nicotinized electronic c...
Detailed Description
Here, we 1) investigate the acute effects of non-nicotinized e-cigarette aerosol inhalation in nonsmokers in terms of blood-based markers of inflammation and oxidative stress, and 2) evaluate their as...
Eligibility Criteria
Inclusion
- • BMI of 18.5 - 30
Exclusion
- Cancer
- HIV
- Mental illness
- Overt cardio- or neurovascular disease (prior heart attack, stroke, transient ischemic attacks)
- Serious arrhythmias
- Bronchospastic disease
- Upper respiratory tract infection within the past six weeks
- Chronic medication or antibiotics
- Claustrophobia / contraindications for MRI
Key Trial Info
Start Date :
May 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT03479203
Start Date
May 22 2018
End Date
August 31 2022
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania, United States, 19104